Fertility and Sterility
Volume 90, Issue 5 , Pages 2016.e7-2016.e10, November 2008

Pregnancy in a hermaphrodite with a male-predominant mosaic karyotype

Kaiser Permanente Southern California, West Los Angeles and Los Angeles Medical Centers, Los Angeles, California

Received 5 January 2008; received in revised form 25 January 2008; accepted 31 January 2008. published online 04 April 2008.

Objective

To report a pregnancy in a hermaphrodite and review of the literature.

Design

Case report and literature review.

Setting

Clinical.

Patient(s)

A patient with male-predominant mosaic karyotype 96% 46XY.

Intervention(s)

Removal of left ovotestis in combination with a supracervical hysterectomy and bilateral salpingo-oophorectomy.

Main Outcome Measure(s)

Identification of published cases of pregnancy and hermaphroditism.

Result(s)

The current patient had previous pregnancy and a wedge biopsy of her left gonad, which demonstrated an ovotestis and an area suspicious for a gonadoblastoma. After delivery of her second pregnancy, the patient underwent a hysterectomy and bilateral salpingo-oophorectomy. The histopathologic evaluation following bilateral oophorectomy demonstrated a residual ovotestis without further evidence of a gonadoblastoma. Review of the literature identified 10 other cases of pregnancy in a hermaphrodite patient.

Conclusion(s)

This is the 11th reported case of fertility in a true hermaphrodite and only the second report of a mosaic true hermaphrodite to demonstrate fertility. This is the only case of a pregnancy involving a male-predominant mosaic 96% 46XY and the only case to confirm the genetics of the offspring.

Key Words: True hermaphrodite, pregnancy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 S.A.S. has nothing to disclose. S.E.L. has nothing to disclose. P.S. has nothing to disclose. M.G.M. is a consultant for Ethicon Women's Health, Covidien, Gynesonics, Karl Storz Endoscopy, and AMAG Pharmaceuticals and is a shareholder in Gynesonics and Impres Medical. S.K. has nothing to disclose.

PII: S0015-0282(08)00233-1

doi:10.1016/j.fertnstert.2008.01.104

Fertility and Sterility
Volume 90, Issue 5 , Pages 2016.e7-2016.e10, November 2008